Loading
Small Cell Lung Cancer / Tarlatamab · Phase 2 Trial
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 registry record for a planned clinical trial of tarlatamab in extensive-stage small-cell lung cancer patients with poor performance status (ECOG 2). No results are reported in this registry entry; the study is actively recruiting and designed to assess 12-month overall survival as the primary endpoint.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Small-cell Lung Cancer; age from 18 Years. Intervention: Tarlatamab. n = 57. 8 sites: Germany.
This is a Phase 2 registry record for a planned clinical trial of tarlatamab in extensive-stage small-cell lung cancer patients with poor performance status (ECOG 2). No results are reported in this registry entry; the study is actively recruiting and designed to assess 12-month overall survival as the primary endpoint.
This is a registry record with no results posted; efficacy, safety, and tolerability data are not yet available. Secondary endpoints (cancer control including brain metastases, tolerability, quality of life) are listed but not yet evaluated.
The source did not state who this applies to in practice.
This is a Phase 2 clinical trial registry record with no results posted; the study is currently recruiting and has not yet generated efficacy or safety data.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07803848). This is a study registration, not published results. Lead sponsor: AIO-Studien-gGmbH. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 57 participants (ESTIMATED). Conditions: Small-cell Lung Cancer. Interventions: DRUG: Tarlatamab. Primary outcome measures: Overall Survival Rate at 12 Months , 12 months. Brief summary: The SPACE-T study is a clinical trial for people with advanced small-cell lung cancer (SCLC) whose cancer has returned or spread despite previous treatment and whose general health is reduced (ECOG performance status 2). The study will include 57 participants at about 15 sites in Germany. The study is testing tarlatamab, a treatment that helps the immune system recognize and attack cancer cells. Participants will receive tarlatamab through a vein, starting with a lower dose of 1 mg, followed by doses of 10 mg. Treatment will then generally be given every two weeks. The main purpose of the study is to find out how effective tarlatamab is in this group of patients by assessing how many participants are alive 12 months after starting the study. The study will also examine how well the treatment controls the cancer, including cancer that has spread to the brain, how well participants tolerate the treatment, its side effects, and its impact on quality of life. Patients with poorer general health are often not included in clinical trials, even though they represent an important part of the people treated for SCLC in everyday clinical practice. The SPACE-T study aims to provide more information about whether tarlatamab is effective and feasible for these patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.